Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00435370 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia
A Phase 3 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 179
- Enrollment target
NCT00435370: Completed Phase 3 study, sponsored by Baylor College of Medicine.
NCT00435370 is a Phase 3 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 179 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00435370, a Phase 3 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 179 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia.
Primary Outcome
The following 8 scales are combined into a single index that is normalized with a mean score of 100 and a standard deviation of 10. Higher scores are considered better cognitive performance. No subscales scores are reported and a final standardized score is reported as the average of the standardized scores on each of these scales. Here is the listing of component scales that were translated into Chinese and used for this study: Brief Assessment of Cognition in Schizophrenia (BACS): Symbol-Codi
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG Tropisetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
What the finished NCT00435370 record still lists
NCT00435370 is an interventional study that assigns participants to a tested intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00435370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00435370 about?
NCT00435370 is a clinical study titled "Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia". This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia.
What is the current status of trial NCT00435370?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 179 participants. The study started on 2006-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00435370?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), Tropisetron (DRUG).
Who is sponsoring clinical trial NCT00435370?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00435370's enrollment target sits among peer trials
179 1437th of 2000 higher than 564 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia